Trazium esilate, formerly known as EGYT-3615, is an adrenergic receptor antagonist potentially for the treatment of major depressive disorder. Trazium esilate is a weak displacer on a1-, a2- and D2-receptors, however, it induced a2-receptor desenzitization after repeated treatment. It had no influence on rat brain cortical noradrenaline and striatal dopamine release evoked by high K+ concentration, but it increased the spontaneous dopamine outflow in rat striatum. References: Gyertyán I, Petocz L, Bajnógel J, Szücs Z, Hegedüs M, Gyüre K, Gacsályi I, Krizsán D, Fekete MI. Possible involvement of the dopaminergic system in the mode of action of the potential antidepressant trazium esilate. Arzneimittelforschung. 1989 Jul;39(7):775-81. PubMed PMID: 2551306.

纯度：≥98%

CAS：97110-59-3